文献速递淋巴瘤

非霍奇金淋巴瘤中的微小残留病——当前应用与未来方向

Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
PubMed 文献 · Br J Haematol · 2017-10-26

本综述概述了基于聚合酶链反应和下一代测序的微小残留病(MRD)检测技术在弥漫大B细胞淋巴瘤、套细胞淋巴瘤和滤泡性淋巴瘤中的应用现状,讨论了其在风险分层、缓解状态监测及指导治疗升级中的已证实和潜在临床价值,并指出未来应用可能识别新MRD标志物、改进初始治疗选择、指导治疗升降级及实时监测克隆演化模式。

要点

  • 非霍奇金淋巴瘤治疗目标是最大化缓解质量与持续时间并最小化治疗相关毒性。
  • 当前判断持续疾病或复发主要依赖影像学和临床评估,敏感性与特异性不完美。
  • 基于聚合酶链反应和下一代测序的MRD监测在非霍奇金淋巴瘤中研究显示有前景。

核心结论

  • MRD监测可能通过在高危患者中强化治疗或对即将复发者早期干预来改变治疗模式。
  • 未来应用可能识别新MRD标志物、改进初始治疗选择、指导治疗升降级及实时监测克隆演化模式,从而重新定义非霍奇金淋巴瘤治疗范式。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 非霍奇金淋巴瘤是一组具有不同治疗范式的异质性肿瘤,但治疗目标均为最大化缓解质量与持续时间并最小化治疗相关毒性。
  • 当前判断持续疾病或复发主要基于影像学和临床评估,这些工具敏感性与特异性不完美。
  • 基于聚合酶链反应和下一代测序的新方法正在非霍奇金淋巴瘤中研究,结果有前景。
  • 本综述概述了MRD技术在弥漫大B细胞淋巴瘤、套细胞淋巴瘤和滤泡性淋巴瘤中的应用现状。
  • 具体讨论了MRD技术在风险分层、缓解状态监测及指导中期和治疗后升级中的已证实和潜在临床价值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-Hodgkin Lymphomas (NHLs) are a heterogeneous group of tumours with distinct treatment paradigms, but in all cases the goal of treatment is to maximize quality and duration of remission while minimizing therapy-related toxicity. Identification of persistent disease or relapse is most often the trigger to intensify or re-initiate anti-neoplastic therapy, respectively. In the current era of NHL treatment, this determination is mostly based on imaging and clinical evaluations, tools with imperfect sensitivity and specificity. The availability of minimal residual disease (MRD) monitoring could transform treatment paradigms by allowing intensification of treatment in at-risk patients or early intervention for impending relapse. Novel methods based on polymerase chain reaction and next-generation sequencing are now being studied in NHL with promising results. This review outlines the current status of the field in the use of MRD techniques for diffuse large B-cell lymphoma, mantle cell lymphoma and follicular lymphoma. Specifically, we address their demonstrated and potential clinical utility in risk stratification, monitoring of remission status, and guiding interim and post-treatment escalation. Future applications of these techniques could identify novel markers of MRD, improve initial treatment selection, guide treatment escalation or de-escalation, and allow for real-time monitoring of patterns of clonal evolution, which together could redefine NHL treatment paradigms.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chase ML, Armand P. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Br J Haematol. 2017. PMID: 29076131. doi:10.1111/bjh.14996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。